Search Results - "Zelenetz, Andrew David"

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL by Zelenetz, Andrew David, Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., López-Jiménez, Javier, Reddy, Nishitha, Mengarelli, Andrea, Phillips, Tycel Jovelle, Musuraca, Gerardo, Sheehy, Oonagh, Li, Joanne, Xu, Weiming, Azoulay, Michel Meyer, Ghalie, Richard, Zinzani, Pier Luigi

“…7511 Background: Zandelisib, a PI3Kδ inhibitor with high target-binding affinity, is administered by intermittent dosing (ID) on days 1-7 of 28-day cycles to…”
Get full text

Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment by Shah, Nirav Niranjan, Jurczak, Wojciech, Zinzani, Pier Luigi, Eyre, Toby A., Cheah, Chan, Ujjani, Chaitra Shankar, Izutsu, Koji, Ma, Shuo, Flinn, Ian W., Alencar, Alvaro Jose, Lewis, David John, Patel, Krish, Maddocks, Kami J., Wang, Yucai, Munir, Talha, Zelenetz, Andrew David, Balbas, Minna, Tsai, Donald E, Wang, Chunxiao, Wang, Michael

“…7514 Background: Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi. Here, we report updated results of pirtobrutinib in patients (pts) with…”
Get full text

Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24) by Pagel, John M., Reddy, Nishitha, Jagadeesh, Deepa, Stathis, Anastasios, Asch, Adam Steven, Salman, Huda S., Kenkre, Vaishalee Padgaonkar, Soumerai, Jacob Drobnyk, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Li, Joanne, Zelenetz, Andrew David

“…Abstract only 7550 Background: FL patients (pts) with POD24 have poorer survival and may benefit from novel therapies at relapse. Zandelisib, a potent,…”
Get full text

Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies by Zelenetz, Andrew David, Reddy, Nishitha, Jagadeesh, Deepa, Stathis, Anastasios, Salman, Huda S., Soumerai, Jacob D., Kenkre, Vaishalee Padgaonkar, Asch, Adam Steven, Llorin-Sangalang, Judith, Li, Joanne, Gorbatchevsky, Igor, Pagel, John M.

“…Abstract only 8016 Background: ME-401, a potent, selective, and structurally differentiated oral PI3kδ inhibitor was evaluated in a dose escalation/expansion…”
Get full text

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance) by Hertz, Daniel Louis, Larson, Nicholas Bradley, Pierpont, Timothy, Bartlett, Nancy L., Zelenetz, Andrew David, Wilson, Wyndham Hopkins, Leonard, John Paul, Jung, Sin-Ho, Riska, Shaun M., Richards, Kristy L.

“…Abstract only e13535 Background: Pediatric patients (pts) receiving long-term vincristine treatment for acute lymphoblastic leukemia (ALL) who carry two…”
Get full text

Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts by Mehta‐Shah, Neha, Lunning, Matthew A., Moskowitz, Alison J., Boruchov, Adam M., Ruan, Jia, Lynch, Peggy, Hamlin, Paul A., Leonard, John, Matasar, Matthew J., Myskowski, Patricia L., Marzouk, Evan, Nair, Sumithra, Sholklapper, Tamir, Minnal, Veena, Palomba, Maria L., Vredenburgh, James, Kumar, Anita, Noy, Ariela, Straus, David J., Zelenetz, Andrew D., Schoder, Heiko, Rademaker, Jurgen, Schaffer, Wendy, Galasso, Natasha, Ganesan, Nivetha, Horwitz, Steven M.

“…Romidepsin (histone deacetylase inhibitor), lenalidomide (immunomodulatory agent), and carfilzomib (proteasome inhibitor), have efficacy and lack cumulative…”
Get full text

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies by Soumerai, Jacob Drobnyk, Jagadeesh, Deepa, Salman, Huda S., Lossos, Izidore S., Asch, Adam Steven, Reddy, Nishitha, Kenkre, Vaishalee Padgaonkar, Pagel, John M., Persky, Daniel O, Awan, Farrukh Tauseef, Magid Diefenbach, Catherine S., Huang, Wenying, Llorin-Sangalang, Judith, Gorbatchevsky, Igor, Zelenetz, Andrew David

“…Abstract only 7553 Background: Dual inhibition of PI3Kδ and BTK pathways may overcome existing or acquired monotherapy resistance. Dual inhibition of these…”
Get full text

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma by Khan, Niloufer, Khimani, Farhad, Shustov, Andrei R., Shadman, Mazyar, Ruan, Jia, Moskowitz, Alison J., Straus, David J., Kumar, Anita, Sauter, Craig Steven, Zelenetz, Andrew David, Noy, Ariela, Shah, Gunjan L., Matasar, Matthew J., Drullinsky, Pamela, Hamilton, Audrey M., Drill, Esther N., Van Besien, Koen, Giralt, Sergio, Horwitz, Steven M., Dahi, Parastoo

“…Abstract only 7533 Background: Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes with conventional chemotherapy. Autologous hematopoietic stem cell…”
Get full text

Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL) by Zelenetz, Andrew David, Jagadeesh, Deepa, Reddy, Nishitha M., Stathis, Anastasios, Salman, Huda S., Asch, Adam Steven, Kenkre, Vaishalee Padgaonkar, Jhangiani, Haresh S., Iasonos, Alexia, Soumerai, Jacob D., Llorin, Judith, Pagel, John M.

“…Abstract only 7512 Background: ME-401, a potent and selective oral PI3kδ inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell…”
Get full text

Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) by Sermer, David J., Vardhana, Santosha Adipudi, Ames, Ashley, Biggar, Erin, Moskowitz, Alison J., Batlevi, Connie Lee, Caron, Philip, Hamilton, Audrey M., Moskowitz, Craig H., Matasar, Matthew J., Zelenetz, Andrew David, Horwitz, Steven M., Von Keudell, Gottfried, Yahalom, Joachim, Rademaker, Jurgen, Dogan, Ahmet, Seshan, Venkatraman E., Younes, Anas

“…Abstract only e20018 Background: Histone deacetylase (HDAC) inhibitors have single agent activity in various types of lymphoma. They have been shown to restore…”
Get full text

Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax by Soumerai, Jacob Drobnyk, Mato, Anthony R., Carter, Jason, Dogan, Ahmet, Hochberg, Ephraim, Barnes, Jeffrey A., Hamilton, Audrey M., Abramson, Jeremy S., Batlevi, Connie Lee, Joffe, Erel, Matasar, Matthew J., Noy, Ariela, Owens, Colette Ngozi, Palomba, Maria Lia, Takvorian, Tak, Flaherty, Kelsey, Ramos, Lauren, Roeker, Lindsey Elizabeth, Abdel-Wahab, Omar Ibrahim, Zelenetz, Andrew David

“…Abstract only 8006 Background: Venetoclax (Ven)-Obinutuzumab (O) is approved for chronic lymphocytic leukemia (CLL) achieving frequent undetectable minimum…”
Get full text

Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab by Ghione, Paola, Joffe, Erel, De Paola, Nadia, Mainardi, Timothy, Noor, Sarah J., Bobillo, Sabela, Myskowski, Patricia L., Palomba, M. Lia, Moskowitz, Alison J., Mato, Anthony R., Sha, Fushen, Von Keudell, Gottfried, Straus, David J., Noy, Ariela, Younes, Anas, Hamlin, Paul A., Brentjens, Renier J., Tejedor-Alonso, Miguel Angel, Horwitz, Steven M., Zelenetz, Andrew David

“…Abstract only 8062 Background: Immunotherapy with anti CD20 is often associated with mild easily manageable infusion reactions. In rare cases, patients…”
Get full text

Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice by Zheng, Serena, Gupta, Kanika, Goyal, Piyush, Nakajima, Reiko, Michaud, Laure, Batlevi, Connie Lee, Hamlin, Paul A., Horwitz, Steven M., Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Moskowitz, Craig H., Noy, Ariela, Palomba, Maria Lia, Straus, David J., Schöder, Heiko, Yahalom, Joachim, Zelenetz, Andrew David, Younes, Anas, Joffe, Erel

“…Abstract only e20017 Background: FDG avidity above liver on interim PET (PET2) during frontline ABVD is considered a marker of impending treatment failure and…”
Get full text

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) by Soumerai, Jacob Drobnyk, Pagel, John M., Jagadeesh, Deepa, Salman, Huda S., Kenkre, Vaishalee Padgaonkar, Asch, Adam Steven, Stathis, Anastasios, Reddy, Nishitha M., Iasonos, Alexia, Ghalie, Richard, Zelenetz, Andrew David

“…Abstract only…”
Get full text

Central nervous system involvement in T-cell lymphomas: A single center experience by Gurion, Ronit, Maragulia, Jocelyn, Zelenetz, Andrew David, Horwitz, Steven M.

“…Abstract only 8069 Background: Large experiences have reviewed the risk of central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL),…”
Get full text

An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies by Soumerai, Jacob Drobnyk, Barrientos, Jacqueline Claudia, Hallek, Michael, Kipps, Thomas J., Jones, Jeffrey Alan, Stilgenbauer, Stephan, Xing, Guan, Yao, Nai-Shun, Ysebaert, Loic, Zelenetz, Andrew David

“…Abstract only…”
Get full text

Management of transaminase elevations in patients receiving idelalisib by Wierda, William G., Coutre, Steven, Flinn, Ian, Gopal, Ajay K., O'Brien, Susan Mary, Salles, Gilles A., Zelenetz, Andrew David, Newcomb, Terry, Waldapfel, Christopher C, Ye, Wei, Ghia, Paolo

“…Abstract only…”
Get full text

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma by Batlevi, Connie Lee, De Frank, Stephanie, Stewart, Caitlin, Hamlin, Paul A., Matasar, Matthew J., Gerecitano, John F., Moskowitz, Alison J., Hamilton, Audrey M., Zelenetz, Andrew David, Drullinsky, Pamela, Straus, David J., Kumar, Anita, Moskowitz, Craig H., Dicostanzo, Joanna, Callan, Devin, Tsui, Dana, Rademaker, Jurgen, Schöder, Heiko, Ni, Ai, Younes, Anas

“…Abstract only…”
Get full text

Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin’s lymphoma (iNHL) in idelalisib (IDELA) trials by Barrientos, Jacqueline Claudia, Ghia, Paolo, Pagel, John, Salles, Gilles A., Sharman, Jeff Porter, Stilgenbauer, Stephan, Gurtovaya, Oksana, Kim, Yeonhee, Philip, Betsy, Zelenetz, Andrew David

“…Abstract only…”
Get full text

Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody by Zelenetz, Andrew David, Mato, Anthony R., Robak, Tadeusz, Jones, Jeffrey Alan, Pagel, John M., Barrientos, Jacqueline Claudia, Brown, Jennifer R., Montillo, Marco, Kipps, Thomas J., Dubowy, Ronald, Xing, Guan, Li, Julia, Hillmen, Peter

“…Abstract only…”
Get full text